← Leaderboards
Lecia V. Sequist
Massachusetts General Hospital
$4,399,201
Attributed
$6,763,623
Total exposure
4
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.3M · FY2011–25$5M$3.8M$2.5M$1.3M$0
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$15,838,033 · 5
By mechanism
P50$9,074,410 · 1
T32$3,053,364 · 1
R01$2,819,737 · 1
R61$468,436 · 1
R21$422,086 · 1
Top collaborators
- Daniel A. Haber6 shared
- David A Barbie4 shared
- Wilhelm Haas2 shared
- Aaron N Hata2 shared
- Jeffrey A Engelman1 shared
Most similar at Massachusetts General Hospital
Same institution · by research overlap
- Ben Z Stanger$14,778,829
- Aaron N Hata$5,868,906
- Andrew T Chan$39,910,857
- Nicholas J Dyson$20,553,237
- Steven E Arnold$15,876,281
Others in their field
Top investigators on “Malignant Neoplasms”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,074,554,219
- Leonard Freedman · Leidos Biomedical Research, Inc.$527,106,485
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$357,875,933
- Richard K. Wilson · Washington University$274,272,747
- Larry Arthur$223,443,122
- Lynn Briscoe · Leidos Biomedical Research, Inc.$186,892,879
Research focus
Malignant NeoplasmsNon-Small-Cell Lung CarcinomaMalignant Neoplasm Of LungCellsResistanceMutationCancer PatientSamplingEpidermal Growth Factor ReceptorEpidermal Growth Factor Receptor Tyrosine Kinase InhibitorGenerationsMutantTargeted TreatmentTumorClinical TrialsClinicLaboratoriesTyrosine Kinase InhibitorNext GenerationDesignProgramsQuality Of LifeInnovationCost
Grant awards (21)
Dana Farber/Harvard Cancer Center SPORE in Lung Cancer$2,250,699
P50 · FY2025 · CA
Training Program in Cancer Biology and Therapeutics$633,473
T32 · FY2025 · CA
A Real-Time AI-Driven High-Throughput Proteomics Data Acquisition Method for Clinical Applications$234,218
R61 · FY2025 · CA
Dana Farber/Harvard Cancer Center SPORE in Lung Cancer$2,250,220
P50 · FY2024 · CA
Training Program in Cancer Biology and Therapeutics$645,802
T32 · FY2024 · CA
A Real-Time AI-Driven High-Throughput Proteomics Data Acquisition Method for Clinical Applications$234,218
R61 · FY2024 · CA
Dana Farber/Harvard Cancer Center SPORE in Lung Cancer$2,189,154
P50 · FY2023 · CA
Training Program in Cancer Biology and Therapeutics$523,031
T32 · FY2023 · CA
Non-genomic resistance mechanisms in EGFR-mutant lung cancer$392,337
R01 · FY2023 · CA
Dana Farber/Harvard Cancer Center SPORE in Lung Cancer$2,384,337
P50 · FY2022 · CA
Training Program in Cancer Biology and Therapeutics$461,088
T32 · FY2022 · CA
Non-genomic resistance mechanisms in EGFR-mutant lung cancer$408,487
R01 · FY2022 · CA
Training Program in Cancer Biology and Therapeutics$403,575
T32 · FY2021 · CA
Training Program in Cancer Biology and Therapeutics$386,395
T32 · FY2020 · CA
Impact of heterogeneity on response to EGFR T790M inhibitors$394,033
R01 · FY2019 · CA · contact PI
Impact of heterogeneity on response to EGFR T790M inhibitors$406,220
R01 · FY2018 · CA · contact PI
Impact of heterogeneity on response to EGFR T790M inhibitors$406,220
R01 · FY2017 · CA · contact PI
Impact of heterogeneity on response to EGFR T790M inhibitors$406,220
R01 · FY2016 · CA · contact PI
Impact of heterogeneity on response to EGFR T790M inhibitors$406,220
R01 · FY2015 · CA
Repeat Biopsies in Lung Cancer to Define Targeted Resistance Mechanisms$230,985
R21 · FY2012 · CA · contact PI
Repeat Biopsies in Lung Cancer to Define Targeted Resistance Mechanisms$191,101
R21 · FY2011 · CA · contact PI